Peer-reviewedCC BY-NC-NDInternal Medicine
Successful Treatment with Epcoritamab for Refractory Diffuse Large B-cell Lymphoma in a Dialysis-dependent Patient
Abstract
The efficacy of epcoritamab in refractory diffuse large B-cell lymphoma (DLBCL) has been established. However, its safety in dialysis-dependent patients is unclear. A 53-year-old man with refractory DLBCL who had received a series of different chemotherapies became dependent on dialysis because of worsening preexisting chronic kidney disease. Epcoritamab was initiated at a standard dose, and a complete response was achieved after the third cycle. However, it was discontinued after the seventh cycle because of the development of lower leg necrosis due to pre-existing arteriosclerosis. Epcoritamab may therefore be feasible with careful monitoring, even in dialysis-dependent patients with refractory DLBCL.
Related
- FDA Approval Summary: Epcoritamab with Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma
- DURABLE PARTIAL RESPONSE TO EPCORITAMAB IN A MULTIPLY RELAPSED/REFRACTORY ELDERLY PATIENT WITH DIFFUSE LARGE B-CELL LYMPHOMA: A CASE REPORT
- Successful salvage therapy with glofitamab followed by selinexor maintenance in an elderly patient with primary refractory diffuse large b-cell lymphoma harboring TP53 and CD58 mutations: a case report and literature review
- Follicular Lymphoma Presenting as Refractory Panniculitis-like Lesions: A Case Report of Successful Salvage with Autologous Stem Cell Transplantation
- Successful treatment with BrECADD in a patient with Dubin-Johnson syndrome and classic Hodgkin lymphoma: a case report.
BibTeX
@article{sasaki2026successful,
title = {{Successful Treatment with Epcoritamab for Refractory Diffuse Large B-cell Lymphoma in a Dialysis-dependent Patient}},
author = {Yuya Sasaki and Keisuke Tanaka and Hisako Nakamaki and Makiko Ogawa and Yoshihiro Umezawa and Masahide Yamamoto and Takehiko Mori},
journal = {Internal Medicine},
year = {2026},
month = jul,
doi = {10.2169/internalmedicine.7556-26},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7556-26/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Successful Treatment with Epcoritamab for Refractory Diffuse Large B-cell Lymphoma in a Dialysis-dependent Patient
AU - Yuya Sasaki
AU - Keisuke Tanaka
AU - Hisako Nakamaki
AU - Makiko Ogawa
AU - Yoshihiro Umezawa
AU - Masahide Yamamoto
AU - Takehiko Mori
PY - 2026
DA - 2026/07/18
JO - Internal Medicine
DO - 10.2169/internalmedicine.7556-26
UR - https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7556-26/_article
AB - The efficacy of epcoritamab in refractory diffuse large B-cell lymphoma (DLBCL) has been established. However, its safety in dialysis-dependent patients is unclear. A 53-year-old man with refractory DLBCL who had received a series of different chemotherapies became dependent on dialysis because of worsening preexisting chronic kidney disease. Epcoritamab was initiated at a standard dose, and a complete response was achieved after the third cycle. However, it was discontinued after the seventh cycle because of the development of lower leg necrosis due to pre-existing arteriosclerosis. Epcoritamab may therefore be feasible with careful monitoring, even in dialysis-dependent patients with refractory DLBCL.
SN - 1349-7235
SN - 0918-2918
ER -